Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
ELTX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Elicio Therapeutics, Inc.NASDAQ: ELTX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $289K rose 4.0% year over year, ahead of the -75.2% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4.0% holds above the trailing-twelve-month pace of -75.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.13M USD
- Year-over-year change
- -4.2%
- 4-year CAGR
- -2.2%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.13M | -4.2% |
| FY2024 | 2024-12-31 | 1.18M | +0.7% |
| FY2023 | 2023-12-31 | 1.17M | +10.7% |
| FY2022 | 2022-12-31 | 1.06M | -14.3% |
| FY2021 | 2021-12-31 | 1.23M | — |
Cost of Revenue vs competitors
How ELTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -75.2% is the 3rd highest of 5, against a peer median of -36.8%.
- Over three fiscal years its annual growth of +2.2% compares with a peer median of -62.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.58M USD | +18.8% | — | 2205.7% | |
| LTM Mar 2026 | CHF 2.61M CHF | -92.3% | -62.9% | — | |
| LTM Mar 2026 | $2.34M USD | — | — | — | |
| LTM Mar 2026 | $1.72M USD | +351.6% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $289K USD | -75.2% | +2.2% | — |
| LTM Mar 2026 | $161K USD | — | — | 5.1% | |
| LTM Mar 2026 | $149K USD | -99.1% | — | — | |
| LTM Mar 2026 | $95K USD | — | — | 5.3% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding ELTX) | — | -36.8% | -62.9% | 5.3% | |
Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.31M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.23M | 1.06M | 1.17M | 1.18M | 1.13M |
| Gross Profit | 27.08M | (1.06M) | (1.17M) | (1.18M) | (1.13M) |
| Gross Margin | 95.6% | — | — | — | — |
| Research & Development | 48.61M | 17.05M | 22.68M | 33.66M | 24.9M |
| Selling, General & Admin | 17.78M | 5.63M | 11.9M | 11.33M | 12.81M |
| Operating Expenses | 66.39M | 22.68M | 34.58M | 43.81M | 36.59M |
| Depreciation & Amortization | 801K | 1.06M | 1.17M | 1.18M | 1.13M |
| EBITDA | (51.93M) | (23.55M) | (32.97M) | (50.27M) | (37.31M) |
| EBITDA Margin | -183.4% | — | — | — | — |
| Operating Income | (39.31M) | (23.73M) | (35.75M) | (44.99M) | (37.71M) |
| Operating Margin | -138.8% | — | — | — | — |
| Interest Income | 3.39K | 64.83K | 373K | 777K | 776K |
| Interest Expense | 876.44K | 3.6M | 1.06M | 455K | 1.13M |
| Other Income / Expenses | (15.27M) | (4.48M) | 550K | (6.91M) | (1.86M) |
| Income Before Tax | (54.57M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Pre-Tax Margin | -192.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.4M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Net Margin | -93.2% | — | — | — | — |
| EPS (Basic) | (19.32) | (9.10) | (6.96) | (4.25) | (2.58) |
| EPS (Diluted) | (19.32) | (9.10) | (6.96) | (4.25) | (2.58) |
| Weighted Avg Shares | 3.2M | 3.1M | 5.06M | 12.2M | 15.31M |
| Weighted Avg Shares (Diluted) | 3.2M | 3.1M | 5.06M | 12.2M | 15.31M |
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.